Patents by Inventor Cristina Lopez-Lopez

Cristina Lopez-Lopez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
    Patent number: 12215387
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Grant
    Filed: June 1, 2022
    Date of Patent: February 4, 2025
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT
    Publication number: 20220316011
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Application
    Filed: June 1, 2022
    Publication date: October 6, 2022
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
    Publication number: 20220211679
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonists for the treatment, amelioration, prevention or delay of progression of fatigue, narcolepsy, excessive daytime sleepiness, nocturnal sleep disturbance, and/or cataplexy.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 7, 2022
    Inventors: Markus FENDT, Dominik FEUERBACH, Donald JOHNS, Cristina LOPEZ-LOPEZ, Kevin Hall MCALLISTER, Judit SOVAGO, Markus WEISS, Baltazar GOMEZ-MANCILLA
  • Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
    Patent number: 11359241
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: June 14, 2022
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • Use of alpha 7 nicotinic acetylcholine receptor agonists
    Patent number: 11311525
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: April 26, 2022
    Assignee: Novartis AG
    Inventors: Markus Fendt, Dominik Feuerbach, Sjoerd Johannes Finnema, Christer Halldin, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Judit Sovago, Markus Weiss
  • Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patents
    Publication number: 20200345746
    Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the prevention of Alzheimer's disease in a patient at risk of developing clinical symptoms of Alzheimer's disease, and in particular, wherein the patient at risk of developing clinical symptoms of Alzheimer's disease carries one or two copies of the ApoE4 allele.
    Type: Application
    Filed: July 17, 2020
    Publication date: November 5, 2020
    Inventors: Cristina LOPEZ-LOPEZ, Ulf NEUMANN
  • Oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy
    Patent number: 10722518
    Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the ApoE4 allele.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 28, 2020
    Assignee: Novartis AG
    Inventors: Cristina Lopez-Lopez, Ulf Neumann, Derya Shimshek
  • OXAZINE DERIVATIVE FOR USE IN THE TREATMENT OR PREVENTION OF CEREBRAL AMYLOID ANGIOPATHY
    Publication number: 20180125853
    Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy and, in particular, wherein the patient carries one or two copies of the ApoE4 allele.
    Type: Application
    Filed: October 11, 2017
    Publication date: May 10, 2018
    Inventors: Cristina LOPEZ-LOPEZ, Ulf NEUMANN, Derya SHIMSHEK
  • Oxazine Derivative for Use in the Prevention of Alzheimer's Disease in at Risk Patients
    Publication number: 20180036315
    Abstract: The present invention relates to an oxazine derivative BACE-1 inhibitor and pharmaceutical compositions comprising such oxazine derivative for use in the prevention of Alzheimer's disease in a patient at risk of developing clinical symptoms of Alzheimer's disease, and in particular, wherein the patient at risk of developing clinical symptoms of Alzheimer's disease carries one or two copies of the ApoE4 allele.
    Type: Application
    Filed: July 17, 2017
    Publication date: February 8, 2018
    Inventors: Cristina LOPEZ-LOPEZ, Ulf NEUMANN
  • BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT
    Publication number: 20180037957
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Application
    Filed: October 20, 2017
    Publication date: February 8, 2018
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
    Publication number: 20170348294
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 7, 2017
    Inventors: Markus FENDT, Dominik FEUERBACH, Sjoerd Jehannes FINNEMA, Baltazar GOMEZ-MANCILLA, Christer HALLDIN, Donald JOHNS, Cristina LOPEZ-LOPEZ, Kevin Hall MCALLISTER, Judit SOVAGO, Markus WEISS
  • Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
    Patent number: 9828642
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: November 28, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS
    Publication number: 20150313884
    Abstract: The invention concerns the use of certain alpha 7 nicotinic acetylcholine receptor agonist for the facilitation of emergence from general anesthesia.
    Type: Application
    Filed: July 15, 2015
    Publication date: November 5, 2015
    Inventors: Markus FENDT, Dominik FEUERBACH, Sjoerd Johannes FINNEMA, Baltazar GOMEZ-MANCILLA, Christer HALLDIN, Donald JOHNS, Cristina LOPEZ-LOPEZ, Kevin Hall MCALLISTER, Judit SOVAGO, Markus WEISS
  • BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT
    Publication number: 20150275303
    Abstract: The invention provides methods for predicting therapeutic responsiveness of a subject suffering from cognitive impairments or dysfunctions, psychotic and/or neurodegenerative disorders to an alpha 7 nicotinic acetylcholine receptor activator treatment.
    Type: Application
    Filed: June 10, 2015
    Publication date: October 1, 2015
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Yunsheng He, Donald Johns, Cristina Lopez-Lopez, Kevin Hall McAllister, Nicole Pezous, Lisa Sandford, Markus Weiss
  • COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
    Publication number: 20140228398
    Abstract: The present invention relates to novel combinations suitable for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease, which comprise, as active ingredients, at least one low molecular weight nicotinic acetylcholine receptor alpha 7 activator and at least one low molecular weight metabotropic glutamate receptor 5 antagonist; to their preparation; to their use as medicaments and to medicaments comprising them.
    Type: Application
    Filed: March 16, 2012
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: Therese Di Paolo, Baltazar Gomez-Mancilla, Cristina Lopez-Lopez, Donal Johns
  • USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS
    Publication number: 20140171448
    Abstract: The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of a Movement Disorder selected from Dystonia, Dyskinesia, Chorea, Restless Legs Syndrome, Tics, Tremor, Myoclonus, Startle, Stiff Person Syndrome, Gait Disorder, Parkinson's Disease and Symptomatic Parkinsonism.
    Type: Application
    Filed: January 20, 2012
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: Dominik Feuerbach, Baltazar Gomez-Mancilla, Cristina Lopez-Lopez, Donald Johns, Thérése Di Paolo